MX2023004205A - Formas en estado solido de lorecivivint. - Google Patents

Formas en estado solido de lorecivivint.

Info

Publication number
MX2023004205A
MX2023004205A MX2023004205A MX2023004205A MX2023004205A MX 2023004205 A MX2023004205 A MX 2023004205A MX 2023004205 A MX2023004205 A MX 2023004205A MX 2023004205 A MX2023004205 A MX 2023004205A MX 2023004205 A MX2023004205 A MX 2023004205A
Authority
MX
Mexico
Prior art keywords
lorecivivint
solid state
state forms
processes
preparation
Prior art date
Application number
MX2023004205A
Other languages
English (en)
Inventor
Alexandr Jegorov
Zuzana Trcková
Adéla Bártová
Pavel Kolesa
Original Assignee
Teva Czech Ind S R O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Czech Ind S R O filed Critical Teva Czech Ind S R O
Publication of MX2023004205A publication Critical patent/MX2023004205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación abarca formas en estado sólido de Lorecivivint, en modalidades, polimorfos cristalinos de Lorecivivint, procesos para la preparación de los mismos y composiciones farmacéuticas de los mismos.
MX2023004205A 2020-10-13 2021-10-12 Formas en estado solido de lorecivivint. MX2023004205A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063090833P 2020-10-13 2020-10-13
US202063120440P 2020-12-02 2020-12-02
US202163157900P 2021-03-08 2021-03-08
PCT/US2021/054465 WO2022081502A1 (en) 2020-10-13 2021-10-12 Solid state forms of lorecivivint

Publications (1)

Publication Number Publication Date
MX2023004205A true MX2023004205A (es) 2023-07-06

Family

ID=79730673

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004205A MX2023004205A (es) 2020-10-13 2021-10-12 Formas en estado solido de lorecivivint.

Country Status (5)

Country Link
US (1) US20230373998A1 (es)
EP (1) EP4229057A1 (es)
KR (1) KR20230087557A (es)
MX (1) MX2023004205A (es)
WO (1) WO2022081502A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
EP3370721A4 (en) 2015-11-06 2019-05-22 Samumed, LLC TREATMENT OF OSTEOARTHRITIS
JP7010851B2 (ja) 2016-06-01 2022-02-10 バイオスプライス セラピューティクス インコーポレイテッド Ｎ－（５－（３－（７－（３－フルオロフェニル）－３Ｈ－イミダゾ［４，５－ｃ］ピリジン－２－イル）－１Ｈ－インダゾール－５－イル）ピリジン－３－イル）－３－メチルブタンアミドを調製するための方法

Also Published As

Publication number Publication date
WO2022081502A1 (en) 2022-04-21
KR20230087557A (ko) 2023-06-16
US20230373998A1 (en) 2023-11-23
EP4229057A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
WO2020141419A3 (en) Novel salts and polymorphic form of bempedoic acid
MX2019015744A (es) Composiciones farmaceuticas.
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
PH12016502103A1 (en) Novel disubstituted 1,2, 4-triazine compound
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
EP4327880A3 (en) Solid state form of ribociclib succinate
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
ZA202207729B (en) Solid state form of pyroxasulfone
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
WO2018193090A3 (en) METHOD FOR PREPARING ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF
WO2016100302A3 (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
WO2022040111A3 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
MX2023004205A (es) Formas en estado solido de lorecivivint.
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
MX2022015597A (es) Formas en estado solido de ciantraniliprol.
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
EP2611446A4 (en) CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR THE PREPARATION OF THE AMORPHOUS FORM OF MARAVIROC
GB202002560D0 (en) Crystalline forms of voxelotor, and processes for the preparation thereof